MYC and cancer: SJ432 is a novel tetrahydroquinoline-like BD2 selective inhibitor that exhibits higher effectiveness than JQ1 in neuroblastoma models in vivo through sustained inhibition of expression of the driver oncoprotein c-MYC.142 This suggests that BD2-selective molecules may retain efficacy while mitigating several kinds of undesirable toxicity linked to excessive dosages of BET inhibitors, providing a strong rationale for the development of BD2-selective BET inhibitors in cancer therapy.